[1] |
TAN P S,, AGUIAR P Jr,, HAALAND B, et al. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer: a systematic review and network meta-analysis of 3 024 participants[J]. Lung Cancer, 2018, 115: 84-88.
doi: 10.1016/j.lungcan.2017.11.017
|
[2] |
HANNA N H,, ROBINSON A G,, TEMIN S, et al. Therapy for stage Ⅳ non-small cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update[J]. J Clin Oncol, 2021, 39(9): 1040-1091.
doi: 10.1200/JCO.20.03570
|
[3] |
ZHAO B,, ZHAO H,, ZHAO J X. Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer[J]. Ther Adv Med Oncol, 2020, 12: 1758835919895753.
|
[4] |
KHUNGER M,, RAKSHIT S,, PASUPULETI V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials[J]. Chest, 2017, 152(2): 271-281.
doi: 10.1016/j.chest.2017.04.177
|
[5] |
SURESH K,, PSOTER K J,, VOONG K R, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy[J]. J Thorac Oncol, 2019, 14(3): 494-502.
doi: 10.1016/j.jtho.2018.11.016
|
6. |
陈康,, 孙步彤. PD-1/PD-L1抑制剂在晚期肿瘤患者中的相关肺炎发生率和发生风险:一项荟萃分析[J]. 中国肺癌杂志, 2020, 23(11): 927-940.
|
|
CHEN K,, SUN B T. Incidence and risk of PD-1/PD-L1 inhibitor-associated pneumonia in advance cancer patients: a meta-analysis[J]. Chin J Lung Cancer, 2020, 23(11): 927-940.
|
[7] |
LIN X Q,, DENG H Y,, CHEN L K, et al. Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience[J]. Transl Lung Cancer Res, 2021, 10(1): 415-429.
doi: 10.21037/tlcr-20-1258
|
[8] |
RASHDAN S,, MINNA J D,, GERBER D E. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy[J]. Lancet Respir Med, 2018, 6(6): 472-478.
doi: 10.1016/S2213-2600(18)30172-3
|
9. |
中华医学会呼吸病学分会肺癌学组. 免疫检查点抑制剂相关肺炎诊治专家共识[J]. 中华结核和呼吸杂志, 2019, 42(11): 820-825.
|
|
Lung Cancer Group, Chinese Thoracic Society, Expert consensus on prevention and treatment of checkpoint inhibitor pneumonitis[J]. Chin J Tuberc Respir Dis, 2019, 42(11): 820-825.
|
[10] |
EL OSTA B,, HU F,, SADEK R, et al. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials[J]. Crit Rev Oncol Hematol, 2017, 119: 1-12.
doi: 10.1016/j.critrevonc.2017.09.002
|
[11] |
YAMAGUCHI T,, SHIMIZU J,, HASEGAWA T, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis[J]. Lung Cancer, 2018, 125: 212-217.
doi: 10.1016/j.lungcan.2018.10.001
|
[12] |
CHO J Y,, KIM J,, LEE J S, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J]. Lung Cancer, 2018, 125: 150-156.
doi: 10.1016/j.lungcan.2018.09.015
|
[13] |
KANAI O,, KIM Y H,, DEMURA Y, et al. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease[J]. Thorac Cancer, 2018, 9(7): 847-855.
doi: 10.1111/1759-7714.12759
|
[14] |
TOI Y,, SUGAWARA S,, SUGISAKA J, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer[J]. JAMA Oncol, 2019, 5(3): 376-383.
doi: 10.1001/jamaoncol.2018.5860
|
[15] |
SURESH K,, NAIDOO J,, LIN C T, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities[J]. Chest, 2018, 154(6): 1416-1423.
doi: 10.1016/j.chest.2018.08.1048
|
[16] |
CUI P F,, LIU Z F,, WANG G Q, et al. Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study[J]. Cancer Med, 2018, 7(8): 4115-4120.
doi: 10.1002/cam4.1579
|
[17] |
LIN X Q,, DENG H Y,, YANG Y L, et al. Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer[J]. Front Oncol, 2021, 11: 698832.
|
[18] |
SURESH K,, VOONG K R,, SHANKAR B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors[J]. J Thorac Oncol, 2018, 13(12): 1930-1939.
doi: 10.1016/j.jtho.2018.08.2035
|
[19] |
ATCHLEY W T,, ALVAREZ C,, SAXENA-BEEM S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina[J]. Chest, 2021, 160(2): 731-742.
doi: 10.1016/j.chest.2021.02.032
|
[20] |
郭寒菲,, 李汶倩,, 崔久嵬. 新辅助免疫治疗在非小细胞肺癌中的研究进展[J]. 肿瘤研究与临床, 2021, 33(1): 65-69.
|
|
GUO H F,, LI W Q,, CUI J W. Progress of neoadjuvant immunotherapy in non-small cell lung cancer[J]. Cancer Res Clin, 2021, 33(1): 65-69.
|
[21] |
MORIYAMA M,, HUGENTOBLER W J,, IWASAKI A. Seasonality of respiratory viral infections[J]. Annu Rev Virol, 2020, 7(1): 83-101.
doi: 10.1146/annurev-virology-012420-022445
|
[22] |
FUKIHARA J,, SAKAMOTO K,, KOYAMA J, et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small cell lung cancer who received programmed death 1 inhibitors[J]. Clin Lung Cancer, 2019, 20(6): 442-450.e4.
doi: 10.1016/j.cllc.2019.07.006
|